Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer.
Saved in:
| Title: | Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer. |
|---|---|
| Authors: | van Wilpe S; Medical Oncology Department, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands. Electronic address: sandra.vanwilpe@radboudumc.nl., Taha T; Institute of Cancer Research and Royal Marsden Hospital, London, UK., Rothmann EC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Altshuler E; Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins, Baltimore, MD, USA., Park J; Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC, USA., Ledet EM; Tulane Cancer Centre, Tulane University, New Orleans, LA, USA., Rothermundt C; Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland., Bergman AM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Willemsen AECAB; Department of Internal Medicine, Tergooi Medical Centre, Hilversum, The Netherlands., Tsantoulis P; Department of Oncology, Geneva University Hospitals, Geneva, Switzerland., Oldenburg J; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Bernard-Tessier A; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France., Fizazi K; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France., Robbrecht DGJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Bruijnen CP; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands., van der Hulle T; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands., Antonarakis ES; Masonic Cancer Centre, University of Minnesota, Minneapolis, MN, USA., Omlin A; Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland., Grönberg H; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Armstrong AJ; Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC, USA., Sartor O; Tulane Cancer Centre, Tulane University, New Orleans, LA, USA., Sena LA; Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins, Baltimore, MD, USA., Beltran H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., de Bono JS; Institute of Cancer Research and Royal Marsden Hospital, London, UK., Mehra N; Medical Oncology Department, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands. |
| Source: | European urology oncology [Eur Urol Oncol] 2025 Aug; Vol. 8 (4), pp. 1020-1029. Date of Electronic Publication: 2025 Jul 12. |
| Publication Type: | Journal Article; Multicenter Study |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
